The aim of this study is to determine the time of incidence of TBI, by measuring the concentration of the biomarkers in CSDH and to investigate which method can be applied to determine the age of CSDH with hemoglobin derivatives.
ID
Source
Brief title
Condition
- Other condition
- Central nervous system vascular disorders
Synonym
Health condition
traumatisch hersenletsel
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The concentration of 6 biomarkers (proteins) in the serum of the CSDH will be
measured with an immunosorbent assay (ELISA) in order to determine the age of
the CSDH.
Secondary outcome
Subsequently, the CSDH will be examined with reflection spectroscopy in order
to measure the amount of hemoglobine derivatives in the CSDH.
Background summary
Studies have shown that age estimation of a CSDH with neuroimages (CT scans en
MRI) is not reliable. A reliable method for the age estimation of the CSDH is
necessary for the forensic field in order to determine the time of incidence of
TBI. The current study will explore two methods for the age estimation of the
CSDH: concentration determination of a group biomarkers* (proteins) and the
determination of the hemoglobin derivatives. It is known that after TBI,
certain cascades of recovery and breakdown occur in the brain, neural
biomarkers (proteins) have an elevated concentration and hemoglobin derivatives
will vary. Over the last decade the AMC forensic photonics group developed new
methods for aging of hematomas (for child abuse recognition) and aging of blood
ex vivo (for dating blood on the crime scene), both a first in the world. These
studies used relative amounts of the various derivatives of hemoglobin to
determine the age of the respective samples.The current study will study the
hemoglobin derivatives in the CSDH samples in order to determine which aging
model is appropriate for CSDH.
By measuring the concentration of the biomarkers in the CSDH (of different
'ages'), an age estimation can be done with a calibration curve (which is
established in this study). As stated, the results are beneficial to the
forensic field because determining the time of incidence of TBI via the age
estimation of the CSDH can aid the reconstruction of activities and this in
turn can be beneficial for the investigation. This information can then be used
in court cases and for that reason these techniques are of high importance.
*Neuronal damage/growth (UCHL1, ICAM-5, NGF); Axonal damage (NFH); Astroglial
cytoskeleton (GFAP); Myelin protein (MBP).
Study objective
The aim of this study is to determine the time of incidence of TBI, by
measuring the concentration of the biomarkers in CSDH and to investigate which
method can be applied to determine the age of CSDH with hemoglobin derivatives.
Study design
This is an observational study in which tests are performed on surgically
removed CSDH that would otherwise be disposed. The method in which the CSDH is
aquired differs minimal from the standard operation procedure, the risk for the
patient is negligible.
Study burden and risks
The procedure to obtain the CSDH differs minimal from the standard operation
procedure, and for that reason the risk for the patiënt will be negligible.
Furthermore, explaining the study may be seen as a small burden by the
patients.
meibergdreef 9
Amsterdam 1105AZ
NL
meibergdreef 9
Amsterdam 1105AZ
NL
Listed location countries
Age
Inclusion criteria
* 18 years.
Mentally competent.
Informed consent.
CSDH as a consequence of traumatic brain injury (TBI).
Month of incidence of TBI is known.
Exclusion criteria
< 18 years.
Not mentally competent.
CSDH not as a consequence of TBI.
Unknown time of incidence of TBI.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL53763.018.15 |